Hormonal
Obesity and metabolic dysfunction are associated with significantly elevated circulating levels of extracellular vesicles (EVs), particularly those derived from platelets, endothelial cells, and adipocytes, which serve as biomarkers for metabolic stress and insulin resistance.
If you have obesity or metabolic syndrome, your body is likely releasing higher levels of extracellular vesicles (EVs) into your blood. These are not just waste; they carry signals that can worsen insulin resistance and inflammation. While there is no direct 'EV treatment' yet, lifestyle interventions like weight loss, diet, and exercise have been shown to reduce these elevated EV levels, suggesting that managing metabolic health directly impacts this signaling pathway.
Obese patients have significantly greater levels of circulating plasma EVs than normal healthy controls and reductions in plasma EVs can be achieved by a low-energy diet, diet plus exercise and weight loss following gastrectomy [26].
Why this rating
The paper is a review citing multiple meta-analyses and independent studies, but notes that precise mechanisms and cargo characterization remain challenging.
Source
Extracellular vesicles in metabolic disease
Naveed Akbar et al. · Diabetologia · 2019
DOI 10.1007/s00125-019-05014-5
More from this paper
- Adipose tissue-derived extracellular vesicles (EVs) mediate communication between adipose tissue and other organs (like the liver), contributing to insulin resistance and systemic metabolic dysfunction in obesity.Good
- Adipose tissue macrophage (ATM)-derived EVs containing miR-155 contribute to glucose intolerance and insulin resistance by suppressing adipogenic transcription factors PPARγ and CEBPβ.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →